Complement Factor Inhibitors for Preventing Synapse Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aberrant activation or insufficient regulation of the complement cascade contributes to numerous diseases and pathological conditions, including neurodegenerative diseases, where premature synapse loss leads to cognitive decline, and timely therapeutic intervention is needed to prevent or reduce synapse loss.
Innovation Solution
Development of compounds represented by formulas I and II, which inhibit or modulate the activity of complement factors such as C1s, thereby preventing excessive synapse elimination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the complement cascade is activated to eliminate pathogens and clear cellular debris, then immune defense is improved, but tissue damage and synapse loss occur due to excessive complement factor activity
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that specifically bind to complement factors (C1s, C3, C5) to modulate their activity. These compounds act as mediators between the immune system's need to eliminate pathogens and the need to prevent tissue damage, providing controlled inhibition of complement cascade activation without completely blocking immune defense functions.
Solution Approach 2:
The patent changes the activity parameter of complement factors by introducing compounds that alter their enzymatic activity levels. By modulating the activity of C1s, C3, and C5 proteases, the system can reduce harmful complement-mediated tissue damage while preserving essential immune defense capabilities, effectively controlling the parameter of complement factor activity to prevent pathology.
2Productivity
If complement factors are allowed to accumulate and activate the cascade, then pathogen clearance is enhanced, but synapse pruning is excessively activated leading to cognitive decline
Solution Approach 1:
Small molecule compounds serve as intermediaries that selectively modulate complement factor activity in the CNS. These compounds can distinguish between peripheral immune responses needed for pathogen clearance and central nervous system processes where synapse maintenance is critical, providing targeted protection against excessive synapse pruning while allowing necessary immune functions to proceed.
Solution Approach 2:
The patent applies local quality control by developing compounds that can selectively inhibit complement activation in specific contexts, particularly in the central nervous system where synapse maintenance is critical. The compounds provide localized modulation of complement activity, allowing pathogen clearance in peripheral tissues while preventing harmful synapse loss in the brain.
3Reliability
If C1r and C1s expression is elevated to enhance complement activation, then immune response is strengthened, but disease pathology progresses due to unchecked protease activity
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that bind to C1r and C1s proteases to modulate their activity. These compounds allow the immune system to maintain elevated C1r and C1s expression levels for strong immune responses while preventing unchecked protease activity that would otherwise drive disease pathology forward through uncontrolled complement cascade activation.
Data Source
AI summary
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.